These biotechs have a long road ahead, but they just might deliver massive growth.
News & Analysis: Jounce Therapeutics, Inc.
JNCE earnings call for the period ending June 30, 2020.
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
JNCE earnings call for the period ending March 31, 2020.
JNCE earnings call for the period ending December 30, 2019.
The biopharma announced full-year 2018 operating results.
The early-stage company's lead drug candidate disappointed in a phase 1/2 study.
All your Motley Fool coverage of the 2018 ASCO Conference in one place.
The clinical-stage upstart reported disappointing news that sparked pessimism.
Find out which of these stocks fell because of earnings concerns.